Axial Spondyloarthritis Disease Activity Cutoffs at Golimumab Initiation in the French GO-PRACTICE Study: Parallels With the German GO-NICE Study.
Axial Spondyloarthritis Disease Activity Cutoffs at Golimumab Initiation in the French GO-PRACTICE Study: Parallels With the German GO-NICE Study.
J Rheumatol. 2020 Oct 15;:
Authors: Goupille P, Harid N, Flipo RM
Abstract
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disorder that includes both radiographic and nonradiographic entities1 International guidelines for axSpA management recommend nonsteroidal antiinflammatory drugs as the first line of treatment2,3.
PMID: 33060324 [PubMed - as supplied by publisher]
Source: J Rheumatol - Category: Rheumatology Authors: Goupille P, Harid N, Flipo RM Tags: J Rheumatol Source Type: research